51
Participants
Start Date
July 3, 2019
Primary Completion Date
April 27, 2021
Study Completion Date
April 27, 2021
Gemtuzumab Ozogamicin
Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
Semmelweis Egyetem I.sz Belgyogyaszati Klinika, Hematologiai Osztaly, Budapest
Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Debrecen
Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvár
Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat - Hematologiai Osztaly, Győr
Hospital Universitario Reina Sofía, Córdoba
Brody School of Medicine at East Carolina University, Greenville
Vidant Medical Center, Greenville
Hospital General Universitario Gregorio Maranon, Madrid
Augusta University Medical Center Clinical Research Pharmacy, Augusta
Georgia Cancer Center at Augusta University, Augusta
Hospital Universitari i Politecnic La Fe, Valencia
University of Alberta Hospital, Edmonton
Research Transition Facility, Edmonton
Kaye Edmonton Clinic, Edmonton
Hamilton Health Sciences, Juravinski Hospital, Hamilton
Juravinski Cancer Centre, Hamilton
Klinika Hematologii i Transplantologii, Gdansk
Uniwersyteckie Centrum Kliniczne, Gdansk
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw
Pracownia Tomografii Komputerowej i Pracownia Rezonansu Magnetycznego, Wroclaw
Hospital de la Santa Creu i Sant Pau, Barcelona
The Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth
Belfast Health and Social Care Trust, Belfast
Clatterbridge Cancer Center NHS Foundation Trust, Liverpool
Lead Sponsor
Pfizer
INDUSTRY